The Memo: Hy2Care Restoring Cartilage and Redefining Recovery

Under the direction of CEO Leo Smit and COO Sanna Severins, Hy2CareⓇ is redefining cartilage repair through a hydrogel implant that enables natural repair of damaged cartilage — without the cost, complexity, or compromise of existing solutions.

Co-founded by Dr. Sanne Both, whose personal battle with failed cartilage surgeries shaped the mission of the company, Hy2Care’s work is rooted in experience and empathy. “Sanne had three cartilage repair surgeries before she turned 24, all of which ultimately failed,” said Smit. “Her experience — and her decision to devote her PhD to solving this problem — is the reason Hy2Care exists.”

The company’s lead product, CartReviveⓇ, is a hydrogel implant designed to rebuild true cartilage, not just scar tissue. As Smit put it: “We don’t offer a refinement of current options — we make a return to biology. This is a repair that lasts and is affordable.”

Origin Story

Hy2Care was founded in 2014 by Dr. Sanne Both and Prof. Marcel Karperien at the University of Twente. Both brought firsthand experience of the shortcomings in existing cartilage treatments. Karperien, a leading voice in cartilage biology, partnered with her to translate frustration into innovation.

Their mission: create a simple, repair solution that could restore joint function without the burden of complex surgeries or prohibitive costs.

Smit, who previously pioneered DSM Biomedical’s implantable materials division, joined as co-investor and CEO during the company’s Seed/A round in 2019. He brings a deep background in soft tissue repair and a passion for building scalable solutions with real-world impact.

Severins followed soon after as co-director. She and Smit had worked together previously and shared a vision for building a company grounded in scientific rigor, practical execution, and team balance. Today, Hy2Care consists of a diverse, multidisciplinary team united by a shared urgency: Patients are waiting; keep moving.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-hy2care-restoring-cartilage-and-redefining-recovery 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more